GEN Exclusives

More »

GEN News Highlights

More »
Apr 1, 2009

Mitsubishi Tanabe Gains Asian Rights to EnVivo’s Cognition-Enhancing Drug

  • Mitsubishi Tanabe Pharma (MTPC) licensed EnVivo Pharmaceuticals’ cognition-enhancing therapy for development and commercialization in Japan and other Asian countries. The candidate, EVP-6124, is in Phase IIa trials in the U.S.

    MTPC will pay an initial license fee as well as clinical, regulatory, and commercial milestones. EnVivo will also receive royalties on sales of EVP-6124 in the MTPC territory, which includes Japan, Korea, Taiwan, Indonesia, and other countries in Asia.

    MTPC plans on initiating Phase I trials during 2010. EVP-6124 is an alpha-7 nicotinic acetylcholine receptor agonist currently being tested by EnVivo in Alzheimer's and schizophrenia patients.

    EnVivo obtained exclusive rights to the alpha-7 agonist program and a related patent estate from Bayer Healthcare in November 2004.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?